Literature DB >> 1283296

Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.

R F Schinazi1, A McMillan, D Cannon, R Mathis, R M Lloyd, A Peck, J P Sommadossi, M St Clair, J Wilson, P A Furman.   

Abstract

2',3'-Dideoxy-5-fluoro-3'-thiacytidine (FTC) has been shown to be a potent and selective compound against human immunodeficiency virus type 1 in acutely infected primary human lymphocytes. FTC is also active against human immunodeficiency virus type 2, simian immunodeficiency virus, and feline immunodeficiency virus in various cell culture systems, including human monocytes. The antiviral activity can be prevented by 2'-deoxycytidine, but not by other natural nucleosides, suggesting that FTC must be phosphorylated to be active and 2'-deoxycytidine kinase is responsible for the phosphorylation. By using chiral columns or enzymatic techniques, the two enantiomers of FTC were separated. The (-)-beta-enantiomer of FTC was about 20-fold more potent than the (+)-beta-enantiomer against human immunodeficiency virus type 1 in peripheral blood mononuclear cells and was also effective in thymidine kinase-deficient CEM cells. Racemic FTC and its enantiomers were nontoxic to human lymphocytes and other cell lines at concentrations of up to 100 microM. Studies with human bone marrow cells indicated that racemic FTC and its (-)-enantiomer had a median inhibitory concentration of > 30 microM. The (+)-enantiomer was significantly more toxic than the (-)-enantiomer to myeloid progenitor cells. The susceptibilities to FTC of pretherapy isolates in comparison with those of posttherapy 3'-azido-3'-deoxythymidine-resistant viruses in human lymphocytes were not substantially different. Similar results were obtained with well-defined 2',3'-dideoxyinosine- and nevirapine-resistant viruses. (-)-FTC-5'-triphosphate competitively inhibited human immunodeficiency virus type 1 reverse transcriptase, with an inhibition constant of 2.9 microM, when a poly(I)n.oligo(dC)19-24 template primer was used. These results suggest that further development of the (-)-Beta-enantiomer of FTC is warranted as an antiviral agent for infections caused by human immunodeficiency viruses.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1283296      PMCID: PMC284347          DOI: 10.1128/AAC.36.11.2423

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  The determination of enzyme inhibitor constants.

Authors:  M DIXON
Journal:  Biochem J       Date:  1953-08       Impact factor: 3.857

2.  The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro.

Authors:  J A Coates; N Cammack; H J Jenkinson; I M Mutton; B A Pearson; R Storer; J M Cameron; C R Penn
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

3.  Synthesis and antiviral activity of various 3'-azido analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1, HTLV-III/LAV).

Authors:  T S Lin; J Y Guo; R F Schinazi; C K Chu; J N Xiang; W H Prusoff
Journal:  J Med Chem       Date:  1988-02       Impact factor: 7.446

4.  Combinations of isoprinosine and 3'-azido-3'-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1.

Authors:  R F Schinazi; D L Cannon; B H Arnold; D Martino-Saltzman
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

5.  Direct comparisons of inhibitor sensitivities of reverse transcriptases from feline and human immunodeficiency viruses.

Authors:  T W North; R C Cronn; K M Remington; R T Tandberg
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

6.  Metabolism of pyrimidine L-nucleosides.

Authors:  M Jurovcik; A Holý
Journal:  Nucleic Acids Res       Date:  1976-08       Impact factor: 16.971

7.  (-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro.

Authors:  J A Coates; N Cammack; H J Jenkinson; A J Jowett; M I Jowett; B A Pearson; C R Penn; P L Rouse; K C Viner; J M Cameron
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

8.  Anti-HIV compound assessment by two novel high capacity assays.

Authors:  D R Averett
Journal:  J Virol Methods       Date:  1989-03       Impact factor: 2.014

9.  Delayed treatment with combinations of antiviral drugs in mice infected with herpes simplex virus and application of the median effect method of analysis.

Authors:  R F Schinazi; T C Chou; R T Scott; X J Yao; A J Nahmias
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

10.  Cellular pharmacology of 3'-azido-3'-deoxythymidine with evidence of incorporation into DNA of human bone marrow cells.

Authors:  J P Sommadossi; R Carlisle; Z Zhou
Journal:  Mol Pharmacol       Date:  1989-07       Impact factor: 4.436

View more
  83 in total

1.  Tautomerism in drug discovery.

Authors:  Alan R Katritzky; C Dennis Hall; Bahaa El-Dien M El-Gendy; Bogdan Draghici
Journal:  J Comput Aided Mol Des       Date:  2010-05-20       Impact factor: 3.686

2.  Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases.

Authors:  Karumanchi V Rao; Marwa S Donia; Jiangnan Peng; Esther Garcia-Palomero; Diana Alonso; Ana Martinez; Miguel Medina; Scott G Franzblau; Babu L Tekwani; Shabana I Khan; Subagus Wahyuono; Kristine L Willett; Mark T Hamann
Journal:  J Nat Prod       Date:  2006-07       Impact factor: 4.050

3.  Pre-steady-state kinetic studies establish entecavir 5'-triphosphate as a substrate for HIV-1 reverse transcriptase.

Authors:  Robert A Domaoal; Moira McMahon; Chloe L Thio; Christopher M Bailey; Julian Tirado-Rives; Aleksander Obikhod; Mervi Detorio; Kimberly L Rapp; Robert F Siliciano; Raymond F Schinazi; Karen S Anderson
Journal:  J Biol Chem       Date:  2007-10-25       Impact factor: 5.157

Review 4.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

Review 5.  Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription.

Authors:  E J Arts; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

6.  A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides.

Authors:  R A Smith; K M Remington; R M Lloyd; R F Schinazi; T W North
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

7.  Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.

Authors:  R F Schinazi; R M Lloyd; M H Nguyen; D L Cannon; A McMillan; N Ilksoy; C K Chu; D C Liotta; H Z Bazmi; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

8.  Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.

Authors:  M Tisdale; S D Kemp; N R Parry; B A Larder
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

Review 9.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.

Authors:  J Balzarini
Journal:  Pharm World Sci       Date:  1994-04-15

10.  Three new manzamine alkaloids from a common Indonesian sponge and their activity against infectious and tropical parasitic diseases.

Authors:  Karumanchi V Rao; Noer Kasanah; Subagus Wahyuono; Babu L Tekwani; Raymond F Schinazi; Mark T Hamann
Journal:  J Nat Prod       Date:  2004-08       Impact factor: 4.050

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.